Biomarker for evaluating disease activity of rheumatoid arthritis and use thereof

摘要

The present invention relates to a biomarker for evaluating disease activity of rheumatoid arthritis and its use, wherein the vascular endothelial growth factor (VEGF) according to the present invention has an increased expression in the serum of patients with rheumatoid arthritis, and disease-controlling antirheumatic drugs (Disease -Modifying antirheumatic drugs (DMARD)), in particular, when treated with biological DMARD (bDMARD), unlike conventional rheumatoid arthritis disease activity evaluation markers, which tend to decrease regardless of the treatment effect, changes in numerical values before and after bDMARD treatment properly reflect the treatment level. It was confirmed that it appeared. Therefore, VEGF according to the present invention is expected to be usefully used in the field of development of a therapeutic agent for rheumatoid arthritis such as evaluation of disease activity before and after treatment for rheumatoid arthritis and screening for a therapeutic agent for rheumatoid arthritis.